European Commission approves pembrolizumab plus lenvatinib as first-line treatment for advanced kidney cancer

The European Commission has approved the combination of pembrolizumab, an anti-PD-1 immunotherapy, plus lenvatinib, an oral tyrosine kinase inhibitor, for the first-line treatment of people with advanced renal cell carcinoma (RCC) for use within the European Union (including Northern Ireland). The approval is based on the results from the phase 3 CLEAR/KEYNOTE-581 trial, in which […]

read more

Health-related quality of life for kidney cancer patients on pembrolizumab/lenvatinib

In this video, Dr Bradley McGregor from the Dana-Farber Cancer Institute in the US and Dr Rana McKay from UC San Diego Health discuss the health-related quality of life of renal cell carcinoma (RCC) patients on the pembrolizumab plus lenvatinib combination. The results from the phase 3 CLEAR/KEYNOTE-581 trial with 1069 RCC patients showed significant […]

read more

FDA approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

The US Food and Drug Administration (FDA) has approved the combination of pembrolizumab, an anti-PD-1 immunotherapy, plus lenvatinib, an oral tyrosine kinase inhibitor, for the first-line treatment of people with advanced renal cell carcinoma (RCC). The approval is based on the results from the phase 3 CLEAR/KEYNOTE-581 trial, in which the combination showed significant improvement […]

read more

Lenvatinib plus pembrolizumab in for untreated and previously treated metastatic kidney cancer

Results from a phase Ib/II study looking at lenvatinib plus pembrolizumab for the treatment of metastatic renal cell carcinoma (RCC) showed that there was a response to treatment and the cancer reduced in size (objective response) in 73% of patients who had not received previous medication for their cancer. There were 143 patients in the […]

read more

ASCO 2021: Health-related quality of life for lenvatinib plus pembrolizumab for advanced kidney cancer

Results from the phase 3 CLEAR study were presented at the American Society for Clinical Oncology (ASCO) Annual Meeting at the weekend. Previous studies have shown that lenvatinib (VEGF inhibitor) used together with pembrolizumab (immune checkpoint inhibitor) resulted in better survival and cancer shrinkage compared to sunitinib when used for patients with advanced renal cell […]

read more

ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

Results from the phase 3 CLEAR study, presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium over the weekend, showed that lenvatinib used in combination with either pembrolizumab or everolimus resulted in improved survival and tumour shrinkage compared to sunitinib when used as a first-line treatment for patients with advanced renal cell […]

read more

Pembrolizumab plus lenvatinib for first-line treatment of kidney cancer shows promise

Results from the phase 3 KEYNOTE-581/CLEAR trial show that the combination of pembrolizumab plus lenvatinib significantly improved the time taken for the cancer to start growing again (progression-free survival), overall survival, and the response rate compared with sunitinib, when used for untreated patients with advanced renal cell carcinoma (RCC). The pembrolizumab/lenvatinib combination had similar side […]

read more

Lenvatinib plus everolimus for non clear cell kidney cancer

Treating non-clear cell renal cell carcinoma (RCC) is challenging because these diseases are rare, and so far there are no effective treatments for this group of patients. Non-clear cell RCC is currently treated in a similar way to clear cell RCC. In a phase 2 clinical trial, 31 patients with non-clear cell RCC were treated […]

read more

Lenvatinib plus pembrolizumab shows promise in solid tumours

The combination of lenvatinib plus pembrolizumab has shown promise in a phase Ib/II clinical trial in 137 patients with various advanced solid tumours and no standard treatment options available. The objective response rate at 24 weeks (the primary objective) was highest in renal cell carcinoma (63%), endometrial cancer (52%), and melanoma (48%). The combination was […]

read more

SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer

We are delighted to announce that the¬†Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of lenvatinib plus everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior VEGF-targeted therapy by NHS Scotland. The lenvatinib plus everolimus¬†combination was accepted following consideration […]

read more
Showing 1 to 10 of 28 results
  TOP